Single-Arm, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of P276-00 in Patients With Relapsed and/or Refractory Mantle Cell Lymphoma.

Trial Profile

Single-Arm, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of P276-00 in Patients With Relapsed and/or Refractory Mantle Cell Lymphoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs P 276 (Primary)
  • Indications Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Sponsors Piramal Phytocare
  • Most Recent Events

    • 26 Jul 2012 Planned end date changed from 1 Dec 2011 to 1 Aug 2012 as reported by ClinicalTrials.gov.
    • 11 Apr 2012 Status changed from active, no longer recruiting to discontinued as reported by Clinical Trials Registry - India.
    • 10 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top